Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Rathkopf DE; Morris MJ; Fox JJ; Danila DC; Slovin SF; Hager JH; Rix PJ; Chow Maneval E; Chen I; Gönen M; Fleisher M; Larson SM; Sawyers CL; Scher HI; Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology, 2013, vol. 31, issue 28, p 3525, ISSN 15277755. ISBN 15277755.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef